Rigel Pharmaceuticals, Incorporated

Mark Irving

Simon Shaw

Somasekhar Bhamidipati

Vanessa Taylor

Esteban Masuda

Jiaxin Yu

Ihab S Darwish

Rao Kolluri

Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.

RIP1K inhibitors

Disclosed are substituted pyridine compounds as well as pharmaceutical compositions and methods of use. One embodiment is a compound having the structure  wherein E, J, T, the ring system denoted by 'B', T, R, R, w and x are as described herein. In certain embodiments, a compound disclosed herein activates the AMPK pathway, and can be used to treat metabolism-related disorders and conditions.

AMPK-activating heterocyclic compounds and methods for using the same

Growing community of inventors

San Francisco, CA, United States of America

Mark Irving